

Freedom of Information Act 2000 - Request Reference FoI/22/402
Metastatic Non-small Cell Lung Cancer

Information Requested:

1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
 - Afatinib
 - Alectinib
 - Atezolizumab monotherapy
 - Atezolizumab in combination
 - Bevacizumab
 - Brigatinib
 - Capmatenib
 - Ceritinib
 - Crizotinib
 - Dacomitinib
 - Dabrafenib with Trametinib
 - Docetaxel monotherapy
 - Durvalumab
 - Erlotinib
 - Gefitinib
 - Gemcitabine
 - Nintedanib with Docetaxel
 - Nivolumab
 - Osimertinib
 - Paclitaxel
 - Pembrolizumab monotherapy
 - Pembrolizumab in combination
 - Pemetrexed with Carboplatin/Cisplatin
 - Tepotinib
 - Vinorelbine with Cisplatin/Carboplatin
 - Any other SACT
 - Palliative care only

Response details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these treatments are provided by Velindre Cancer Centre, please see their contact details below:

foi.vunhst@wales.nhs.uk Or,

Velindre NHS Trust Headquarters.
Unit 2 Charnwood Court,
Parc Nantgarw,
Nantgarw,
Cardiff.
CF15 7QZ